Exploring a new treatment target for myelofibrosis
MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis
This study is looking at a new way to help people with myelofibrosis, a tough blood cancer, by exploring how a protein called MYC affects the disease and finding new treatments for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11089310 on NIH RePORTER |
What this research studies
This research investigates the MYC-alarmin axis as a potential new therapeutic target for patients with myelofibrosis, a serious blood cancer characterized by bone marrow fibrosis and a high risk of transformation to acute myeloid leukemia. The study aims to understand how MYC, a protein involved in cell growth and survival, contributes to the disease and how targeting this pathway could improve treatment outcomes. By analyzing genetic mutations and their effects on disease progression, the research seeks to develop innovative therapies that could benefit patients who do not respond well to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myelofibrosis, particularly those who have not responded adequately to current JAK2 inhibitor therapies.
Not a fit: Patients with myelofibrosis who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival and quality of life for patients with myelofibrosis.
How similar studies have performed: While the MYC-alarmin axis is a novel approach in the context of myelofibrosis, similar strategies targeting oncogenic pathways have shown promise in other hematologic malignancies.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Yun, Seongseok — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Yun, Seongseok
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.